First-Line Treatment of HER2-Positive Metastatic Breast Cancer

DESTINY-Breast12 Intracranial activity of TDXd in HER2-positive Patients with brain metastasesПодробнее

Making Precision Decisions in High-Risk HR+, HER2- Metastatic Breast CancerПодробнее

Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer | Dr. Jitendra PahlajaniПодробнее

How do we approach metastatic HER2 positive breast cancer?Подробнее

Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal adenocarcinomaПодробнее

Medical advances in the treatment of metastatic breast cancerПодробнее

Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer ParadigmПодробнее

Advancements and Applications of Antibody Drug Conjugates in HER2-Negative Breast CancerПодробнее

124. Metastatic HER2- Positive Breast CancerПодробнее

Navigating the Integration of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast CancerПодробнее

Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast CancerПодробнее

Expert Exchange: Clinical Implications of the Latest Advances in Metastatic Breast CancerПодробнее

Breast Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Erika HamiltonПодробнее

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancerПодробнее

Addressing Current Questions and Controversies in the Management of Metastatic Breast CancerПодробнее

Latest Update on HER2-Low Breast Cancer and Implications for Clinical PracticeПодробнее

HER2-Positive Metastatic Colorectal Cancer: Unraveling Game-Changing Treatment ApproachesПодробнее

Emerging Systemic Treatment Options Across the Spectrum of Breast Cancer TherapyПодробнее

Dr Bardia on Current Approaches to HER2+ Breast Cancer ManagementПодробнее

Dr Waks on Key Questions Regarding the First-Line Use of T-DXd in HER2+ Breast CancerПодробнее